Trijardy XR

Trijardy XR · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 15, 2027

282 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (103)

Dec 8, 2037patentUS 12364700*PED
Dec 8, 2037patentUS 12364700*PED
Dec 8, 2037patentUS 12364700*PED
Dec 8, 2037patentUS 12364700*PED
Jun 8, 2037method-of-use (U-4224)US 12364700
Jun 8, 2037method-of-use (U-4224)US 12364700
Jun 8, 2037method-of-use (U-4224)US 12364700
Jun 8, 2037method-of-use (U-4224)US 12364700
Dec 11, 2034patentUS 9949998*PED
Dec 11, 2034patentUS 9949998*PED
Dec 11, 2034patentUS 9949998*PED
Dec 11, 2034patentUS 9949998*PED
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 10258637*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11090323*PED
Oct 3, 2034patentUS 11833166*PED
Oct 3, 2034patentUS 11833166*PED
Oct 3, 2034patentUS 11833166*PED
Oct 3, 2034patentUS 11833166*PED
Jun 11, 2034method-of-use (U-2731)US 9949998
Jun 11, 2034method-of-use (U-2731)US 9949998
Jun 11, 2034method-of-use (U-2731)US 9949998
Jun 11, 2034method-of-use (U-2731)US 9949998
Apr 3, 2034method-of-use (U-2731)US 10258637
Apr 3, 2034method-of-use (U-2731)US 10258637
Apr 3, 2034method-of-use (U-2731)US 10258637
Apr 3, 2034method-of-use (U-2731)US 10258637
Apr 3, 2034method-of-use (U-3192)US 11090323
Apr 3, 2034method-of-use (U-3192)US 11090323
Apr 3, 2034method-of-use (U-3192)US 11090323
Apr 3, 2034method-of-use (U-3192)US 11090323
Apr 3, 2034method-of-use (U-3777)US 11833166
Apr 3, 2034method-of-use (U-3777)US 11833166
Apr 3, 2034method-of-use (U-3777)US 11833166
Apr 3, 2034method-of-use (U-3777)US 11833166
Mar 7, 2032formulationUS 10596120
Mar 7, 2032formulationUS 10596120
Mar 7, 2032formulationUS 10596120
Mar 7, 2032formulationUS 10596120
Mar 7, 2032formulationUS 11564886
Mar 7, 2032formulationUS 11564886
Mar 7, 2032formulationUS 11564886
Aug 11, 2030patentUS 12115179*PED4.1y
Aug 11, 2030patentUS 12115179*PED4.1y
Aug 11, 2030patentUS 12115179*PED4.1y
Aug 11, 2030patentUS 12115179*PED4.1y
Jun 15, 2030formulationUS 104061723.9y
Jun 15, 2030formulationUS 104061723.9y
Jun 15, 2030formulationUS 104061723.9y
Jun 15, 2030formulationUS 104061723.9y
May 21, 2030formulationUS 91557053.9y
May 21, 2030formulationUS 91557053.9y
May 21, 2030formulationUS 91557053.9y
May 21, 2030formulationUS 91557053.9y
Apr 14, 2030patentUS 8551957*PED3.8y
Apr 14, 2030patentUS 8551957*PED3.8y
Apr 14, 2030patentUS 8551957*PED3.8y
Apr 14, 2030patentUS 8551957*PED3.8y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Feb 11, 2030method-of-use (U-4023)US 121151793.6y
Oct 14, 2029formulationUS 85519573.3y
Oct 14, 2029formulationUS 85519573.3y
Oct 14, 2029formulationUS 85519573.3y
Oct 14, 2029formulationUS 85519573.3y
Apr 2, 2029formulationUS 100223792.7y
Apr 2, 2029formulationUS 100223792.7y
Apr 2, 2029formulationUS 100223792.7y
Apr 2, 2029formulationUS 100223792.7y
Apr 2, 2029formulationUS 94150162.7y
Apr 2, 2029formulationUS 94150162.7y
Apr 2, 2029formulationUS 94150162.7y
Apr 2, 2029formulationUS 94150162.7y
Feb 1, 2029patentUS 7579449*PED2.6y
Feb 1, 2029patentUS 7579449*PED2.6y
Feb 1, 2029patentUS 7579449*PED2.6y
Feb 1, 2029patentUS 7579449*PED2.6y
Aug 1, 2028compositionUS 75794492.1y
Aug 1, 2028compositionUS 75794492.1y
Aug 1, 2028compositionUS 75794492.1y
Aug 1, 2028compositionUS 75794492.1y
Oct 15, 2027patentUS 7713938*PED1.3y
Oct 15, 2027patentUS 7713938*PED1.3y
Oct 15, 2027patentUS 7713938*PED1.3y
Oct 15, 2027patentUS 7713938*PED1.3y
Apr 15, 2027compositionUS 7713938282d
Apr 15, 2027compositionUS 7713938282d
Apr 15, 2027compositionUS 7713938282d
Apr 15, 2027compositionUS 7713938282d
May 26, 2026patentUS 8883805*PED
May 26, 2026patentUS 8883805*PED
May 26, 2026patentUS 8883805*PED
May 26, 2026patentUS 8883805*PED
Nov 26, 2025formulationUS 8883805
Nov 26, 2025formulationUS 8883805
Nov 26, 2025formulationUS 8883805
Nov 26, 2025formulationUS 8883805

(empagliflozin + linagliptin + metformin hydrochloride) ER

indications

all catalysts(7)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside

Patent cliff

patents (103)